The Community Resource in Targeted Therapies
Driving Knowledge. Empowering Change. Optimizing Outcomes.
ONCAlert | Upfront Therapy for mRCC
Videos  >  

Safety Findings for Axi-Cel in Patients With DLBCL

Brian T. Hill, MD, PhD
Published Online:3:44 PM, Thu February 14, 2019


Brian T. Hill, MD, PhD, a physician in the Department of Hematology and Medical Oncology at the Cleveland Clinic, discusses the safety findings from the ZUMA-1 trial investigating axicabtagene ciloleucel (KTE-C19, axi-cel) in patients with diffuse large B-cell lymphoma.

In addition to the efficacy results that demonstrated a complete remission rate around 40% and an overall response rate even higher, the safety findings are comparable to what has been previously seen. Hill says this is in terms of cytokine release syndrome and encephalopathy.

While these patients are somewhat older with poor performance statuses, Hill concludes that this regimen is safe to treat with in this patient population.
Copyright © TargetedOnc 2018 Intellisphere, LLC. All Rights Reserved.